Advertisement
UK markets close in 2 hours 20 minutes

  • FTSE 100

    8,067.04
    +26.66 (+0.33%)
     

  • FTSE 250

    19,651.01
    -68.36 (-0.35%)
     

  • AIM

    754.15
    -0.54 (-0.07%)
     

  • GBP/EUR

    1.1668
    +0.0024 (+0.20%)
     

  • GBP/USD

    1.2473
    +0.0011 (+0.09%)
     

  • Bitcoin GBP

    50,574.00
    -2,456.24 (-4.63%)
     

  • CMC Crypto 200

    1,349.83
    -32.74 (-2.37%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    82.99
    +0.18 (+0.22%)
     

  • GOLD FUTURES

    2,341.80
    +3.40 (+0.15%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,900.66
    -188.04 (-1.04%)
     

  • CAC 40

    7,981.32
    -110.54 (-1.37%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

Number of Shares and Voting Rights of ADOCIA as of April 30th, 2023

Business Wire
·2-min read

LYON, France, May 16, 2023--(BUSINESS WIRE)--Regulatory News:

Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with innovative formulations of approved proteins, releases its total number of outstanding shares as well as its voting rights as of April 30th, 2023.

Month

Date

Total number of outstanding shares

Total number of theoretical voting rights (1)

Total number of exercisable voting rights (2)

April

04/30/2023

8,970,451

11,741,836

11,699,203

*including 15,565 new shares resulting from the conversion of 40,000 bonds convertible into shares (OC 1124) issued by the Company on December 1, 2022. The main characteristics are described in the press releases of the days of issue.

ADVERTISEMENT

(1) The total number of theoretical voting rights (or "gross" voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.

(2) The total number of exercisable voting rights (or" net" voting rights) is calculated without taking into account the shares with suspended voting rights, in this case, shares held by the Company in the context of a liquidity agreement.

About Adocia

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The company has a broad portfolio of drug candidates based on three proprietary technology platforms:

1) The BioChaperone® technology for the development of new generation insulins and products combining insulins with other classes of hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell® Islets, an immunoprotective biomaterial for cell transplantation with a first application in pancreatic cells transplantation for patients with "brittle" diabetes.

Adocia holds more than 25 patent families.

Based in Lyon, the company has 105 employees. Adocia is listed on the EuronextTM Paris market (Euronext: ADOC; ISIN: FR0011184241).

Disclaimer

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those which are set forth in the "Risk Factors" section of the universal registration document that was filed with the French Autorité des marchés financiers on April 26, 2023 (a copy of which is available at www.adocia.com), in particular uncertainties that are linked to research and development, future clinical data, analyses, and the evolution of the economic context, the financial markets and the markets in which Adocia operates.
The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia as of this day. The occurrence of all or part of such risks could cause that actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005842/en/

Contacts

Adocia

Olivier Soula
CEO
contactinvestisseurs@adocia.com
Tel : +33 4 72 610 610
www.adocia.com

Adocia Press and Investors Relations

Ulysse Communication
Pierre-Louis Germain
Margaux Puech Pays d’Alissac
Bruno Arabian
adocia@ulysse-communication.com
+33 (0)6 64 79 97 51